1,600
Participants
Start Date
February 28, 2005
Study Completion Date
May 31, 2008
MPC-7869
oral 800 mg BID
MPC-7869
Oral BID dosing
New York
New York
New York
Elmsford
Brooklyn
Brooklyn
Albany
Syracuse
Rochester
Olean
Pittsburgh
Pittsburgh
Scotland
Bala-Cynwyd
Jenkintown
Philadelphia
Philadelphia
Philadelphia
Washington D.C.
Glen Burnie
Baltimore
Alexandria
Charlottesville
Virginia Beach
Winston-Salem
Durham
Greer
Beaufort
Decatur
Atlanta
Jacksonville
Jacksonville
Orlando
Hialeah
Hollywood
Pompano Beach
Derrfield Beach
Miami
Bay Harbor
North Miami
Fort Lauderdale
Plantation
West Palm Beach
Boca Raton
Tampa
Tampa
Tampa
Tampa
Fort Myers
Fort Myers
Naples
Ocala
Alabaster
Huntsville
Nashville
Johnson City
Memphis
Lexington
Columbus
Toledo
Cincinnati
Centerville
Indianapolis
Fort Wayne
Farmington Hills
Grand Rapids
Milwaukee
Middleton
Rochester
Chicago
St Louis
Kansas City
New Orleans
Little Rock
Oklahoma City
Oklahoma City
Oklahoma City
Dallas
Wichita Falls
Houston
San Antonio
Austin
Denver
Salt Lake City
Salt Lake City
Ogden
Phoenix
Mesa
Sun City
Peoria
Albuquerque
Los Angeles
La Jolla
Long Beach
Oceanside
Vista
San Diego
Rancho Mirage
Laguna Hills
Newport Beach
Newport Beach
Fresno
San Francisco
San Francisco
Lafayette
Sacramento
Portland
Portland
Eugene
Tucson
Irvine
Danbury
Darien
New Haven
Clearwater
Boston
Brockton
West Yarmouth
Lebanon
Kenilworth
Morristown
Piscataway
Princeton
Stratford
Toms River
Raleigh
East Providence
East Providence
Providence
North Charleston
Galveston
Bennington
Lead Sponsor
Myrexis Inc.
INDUSTRY